Compare TAOP & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TAOP | BLRX |
|---|---|---|
| Founded | 1993 | 2003 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8M | 12.6M |
| IPO Year | 2012 | 2010 |
| Metric | TAOP | BLRX |
|---|---|---|
| Price | $1.30 | $3.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 5.8K | ★ 22.7K |
| Earning Date | 05-12-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.25 | $2.15 |
| 52 Week High | $8.78 | $7.77 |
| Indicator | TAOP | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.33 | 56.61 |
| Support Level | $1.20 | $2.66 |
| Resistance Level | $1.59 | $3.11 |
| Average True Range (ATR) | 0.06 | 0.24 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 70.61 | 57.43 |
Taoping Inc is a provider of cloud-based technology solutions, smart city IoT platforms, digital advertising delivery systems, and internet-based information distribution systems in China. The company has three reportable segments. The Cloud-based Technology segment includes cloud-based products, high-end data storage servers, advertising services, and customized software solutions for private sector customers. The Traditional Information Technology segment includes project-based technology products and services sold to the public sector, including Geographic Information Systems, Digital Public Security Technology, and Digital Hospital Information Systems. The Smart Elevator segment provides elevator sales, installation, maintenance, renovation, and cloud-based maintenance services.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.